Online First

FDA Oncology Update

FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants

FDA Oncology Update

Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia

FDA Oncology Update

Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation

FDA Oncology Update

FDA Approved Aphexda, in Combination With Filgrastim, to Mobilize Stem Cells for Transplant in Patients With Multiple Myeloma

FDA Oncology Update

Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma

FDA Oncology Update

Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer

FDA Oncology Update

Temodar Receives FDA Approval for New and Updated Indications and Doses Through the Project Renewal Program

JHOP - October 2023 Vol 13, No 5

Original Article

Tolerance of Oral Targeted Agents in Patients With Advanced or Metastatic RCC With and Without Renal Impairment

Original Article

Clinical, Laboratory, and Genetic Profiles and Outcomes of Patients With aHUS and Restrictive Use of Eculizumab: A Single-Center Experience

Practical Issues in Pharmacy Management

Enhancing Pharmacovigilance Methodologies in Patients With Cancer at Infusion Centers

Editorial

Are We Ready for Same-Day Pegfilgrastim and Chemotherapy?

Practical Issues in Pharmacy Management

Clinical Role of Oncology Pharmacy Specialists in Oral Oncolytic Management in the Outpatient Hematology Clinic Setting

Original Article

Evaluation of Same-Day Versus Next-Day Administration of Pegfilgrastim in Patients With Breast Cancer

Meeting Highlights

Zanidatamab Plus Docetaxel Shows Promising Antitumor Activity in Advanced HER2-Positive Breast Cancer

Prolonged Effectiveness With Tucatinib Plus Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer

Inetetamab Plus Camrelizumab and Utidelone Safe and Effective in Patients With HER2-Positive Metastatic Breast Cancer

FDA Oncology Update

Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion

FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation

FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

Most Popular Articles

JHOP - October 2023 Vol 13, No 5 - Practical Issues in Pharmacy Management

Clinical Role of Oncology Pharmacy Specialists in Oral Oncolytic Management in the Outpatient Hematology Clinic Setting

JHOP - August 2023 Vol 13, No 4 - Original Article

Effects of Vascular Endothelial Growth Factor Inhibitor–Induced Proteinuria on Treatment Course and Outcomes: Retrospective Analysis and Review of the Literature

JHOP - August 2023 Vol 13, No 4 - Review Article

A Review of Clinical Data Among Biosimilars: Just How Similar Are They?

JHOP - August 2023 Vol 13, No 4 - Practical Issues in Pharmacy Management

Impact of Pharmacist-Led Oral Chemotherapy Telehealth Clinic at a Community Cancer Center Using the TAMER Model

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.